NEM vs NKTR · P/E 14, rev $13.43B vs rev $21.0M
Newmont Goldcorp Corp (NEM) versus Nektar Therapeutics (NKTR) — a side-by-side from cached financials, not a winner call.
Newmont Goldcorp Corp (NEM) is a gold company listed on NYSE.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Latest reported NEM revenue for 2026-06-30 was $13.43B. Net income was $5.46B. Revenue was up 83.7% from 2026-03-31 to 2026-06-30. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
NEM currently screens at market cap $112.81B and trailing P/E 13.7. NKTR currently screens at market cap $307.2M.
Not investment advice. Open the NEM and NKTR stock pages for the full models.
Not investment advice.